European Journal of Heart Failure

Papers
(The H4-Index of European Journal of Heart Failure is 64. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Epidemiology of heart failure931
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure803
Myocardial localization of coronavirus in COVID‐19 cardiogenic shock714
Universal definition and classification of heart failure: a report of the Heart Failure Society of America, Heart Failure Association of the European Society of Cardiology, Japanese Heart Failure Soci595
Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio‐O355
Epidemiology, pathophysiology and contemporary management of cardiogenic shock – a position statement from the Heart Failure Association of the European Society of Cardiology239
Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), th220
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial191
COVID‐19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease187
Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio‐Oncology Study Group of the Heart Failure Association and180
Self‐care of heart failure patients: practical management recommendations from the Heart Failure Association of the European Society of Cardiology174
Heart failure in COVID‐19 patients: prevalence, incidence and prognostic implications167
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology158
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial 155
The impact of COVID‐19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic149
Pulmonary artery pressure‐guided therapy in ambulatory patients with symptomatic heart failure: the CardioMEMS European Monitoring Study for Heart F144
The Heart Failure Association Atlas: Heart Failure Epidemiology and Management Statistics 2019127
Prevalence and prognostic impact of the coexistence of multiple frailty domains in elderly patients with heart failure: the FRAGILE‐HF cohort study119
Angiotensin‐converting enzyme inhibitors and angiotensin II receptor blockers are not associated with severe COVID‐19 infection in a multi‐site UK acute hospital trust113
Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy105
Efficacy and safety of tafamidis doses in the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial (ATTR‐ACT) and long‐term extension study102
Circulating cardiovascular microRNAs in critically ill COVID‐19 patients100
Depression and heart failure: the lonely comorbidity99
Optimized implementation of cardiac resynchronization therapy: a call for action for referral and optimization of care98
Sodium–glucose co‐transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology96
Primary results of long‐term outcomes in the MOMENTUM 3 pivotal trial and continued access protocol study phase: a study of 2200 HeartMate 3 left ventricular assist device implan96
Impact of heart failure on the clinical course and outcomes of patients hospitalized for COVID‐19. Results of the Cardio‐COVID‐Italy multicentre study95
Management of heart failure patients with COVID‐19: a joint position paper of the Chinese Heart Failure Association & National Heart Failure Committee and the Heart Failure Association 93
Characterization of the inflammatory‐metabolic phenotype of heart failure with a preserved ejection fraction: a hypothesis to explain influence of sex on the evolution and potential treatme91
An expert consensus document on the management of cardiovascular manifestations of Fabry disease91
Integration of a palliative approach into heart failure care: a European Society of Cardiology Heart Failure Association position paper90
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR‐Preserved trial88
A Phase II study of autologous mesenchymal stromal cells and c‐kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT‐HF87
Ultrasound imaging of congestion in heart failure: examinations beyond the heart87
Cost‐effectiveness of dapagliflozin as a treatment for heart failure with reduced ejection fraction: a multinational health‐economic analysis of DAPA‐HF86
Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association (HFA) 84
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction84
Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failure83
Unravelling the interplay between hyperkalaemia, renin–angiotensin–aldosterone inhibitor use and clinical outcomes. Data from 9222 chronic heart failure patients of the ESC‐HFA‐EORP Heart Failure Long83
Temporal trends in decompensated heart failure and outcomes during COVID‐19: a multisite report from heart failure referral centres in London82
The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE81
Effects of empagliflozin on renal sodium and glucose handling in patients with acute heart failure80
Heart failure drug titration, discontinuation, mortality and heart failure hospitalization risk: a multinational observational study (US, UK and Sweden)80
Telemonitoring versus standard care in heart failure: a randomised multicentre trial77
Impact of tricuspid regurgitation on survival in patients with heart failure: a large electronic health record patient‐level database analysis76
Association of COVID‐19 with impaired endothelial glycocalyx, vascular function and myocardial deformation 4 months after infection76
Cardiotoxicity associated with immune checkpoint inhibitor therapy: a meta‐analysis75
Haemodynamic characteristics of COVID‐19 patients with acute respiratory distress syndrome requiring mechanical ventilation. An invasive assessment using right heart catheterization73
Trial characteristics associated with under‐enrolment of females in randomized controlled trials of heart failure with reduced ejection fraction: a systematic review73
Cachexia, muscle wasting, and frailty in cardiovascular disease71
Minimal clinically important difference in quality of life scores for patients with heart failure and reduced ejection fraction70
Circulating heart failure biomarkers beyond natriuretic peptides: review from the Biomarker Study Group of the Heart Failure Association (HFA), European Society of Cardiology (ESC70
Machine learning based on biomarker profiles identifies distinct subgroups of heart failure with preserved ejection fraction70
Unveiling outcomes in coexisting severe aortic stenosis and transthyretin cardiac amyloidosis69
Characterization of NT‐proBNP in a large cohort of COVID‐19 patients68
Regional adiposity and heart failure with preserved ejection fraction68
Immunogenicity of the BNT162b2 mRNA vaccine in heart transplant recipients – a prospective cohort study68
Trends in prevalence of comorbidities in heart failure clinical trials67
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction67
Identification of distinct phenotypic clusters in heart failure with preserved ejection fraction66
Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta‐regression in the past four decades66
Heart Failure Association of the European Society of Cardiology update on sodium–glucose co‐transporter 2 inhibitors in heart failure65
Management of low blood pressure in ambulatory heart failure with reduced ejection fraction patients65
Obesity, venous capacitance, and venous compliance in heart failure with preserved ejection fraction64
0.083468914031982